Vascular surgical antibiotic prophylaxis study (VSAPS)

Area of Science:

• Infectious Diseases
• Surgical Infections
• Pharmacology

Background:

• Surgical site infections (SSIs) are a significant concern in vascular procedures.
• Methicillin-resistant Staphylococcus aureus (MRSA) is a common pathogen in SSIs.
• Current prophylactic regimens aim to prevent bacterial contamination during surgery.

Purpose of the Study:

• To evaluate the efficacy of adding vancomycin or daptomycin to cefazolin for surgical prophylaxis in low-risk vascular surgery patients.
• To determine if enhanced antibiotic coverage reduces the incidence of overall and MRSA infections.
• To assess the impact of different antibiotic combinations on infectious complications.

Main Methods:

• Prospective, randomized, single-institution study.
• 169 low-risk patients undergoing elective vascular procedures.
• Randomized to cefazolin, cefazolin + vancomycin, or cefazolin + daptomycin prophylaxis.

Main Results:

• Overall infections: Cefazolin (12.9%), Cefazolin + Vancomycin (12.5%), Cefazolin + Daptomycin (3.92%).
• MRSA infections: Cefazolin (3.23%), Cefazolin + Vancomycin (7.14%), Cefazolin + Daptomycin (0%).
• A trend toward fewer infectious complications was observed with cefazolin + daptomycin.

Conclusions:

• Adding anti-MRSA agents (vancomycin or daptomycin) to cefazolin did not significantly reduce MRSA infection rates in this low-risk population.
• The combination of cefazolin and daptomycin showed a trend towards fewer overall infections.
• Standard cefazolin prophylaxis may be sufficient for low-risk vascular surgery patients regarding MRSA prevention.